Intermittent preventive treatment of malaria in infancy

The Lancet

Volumn 374, Issue 9700, 2009, Pages 1478-1480

  McGready, Rose ^a  

^a SHOKLO MALARIA RESEARCH UNIT   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROGUANIL PLUS DAPSONE; FANSIDAR; MEFLOQUINE; PLACEBO;

ARTICLE; CLINICAL OBSERVATION; COST CONTROL; DRUG ELIMINATION; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; GROUPS BY AGE; HUMAN; INFANCY; MALARIA; MALARIA CONTROL; MORTALITY; PRIORITY JOURNAL;

EID: 70350565497     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61629-9     Document Type: Note

References (12)

1. Abacassamo F., Enosse S., Aponte J.J., et al. Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria. Trop Med Int Health 9 (2004) 200-208
2. Bousema J.T., Gouagna L.C., Meutstege A.M., et al. Treatment failure of pyrimethamine-sulphadoxine and induction of Plasmodium falciparum gametocytaemia in children in western Kenya. Trop Med Int Health 8 (2003) 427-430
3. Checchi F., Piola P., Kosack C., et al. Antimalarial efficacy of sulfadoxine-pyrimethamine, amodiaquine and a combination of chloroquine plus sulfadoxine-pyrimethamine in Bundi Bugyo, western Uganda. Trop Med Int Health 9 (2004) 445-450
4. Djaman J., Abouanou S., Basco L., and Kone M. Limits of the efficacy of chloroquine and sulfadoxine-pyrimethamine in Northern Abidjan (Côte d'Ivoire): combined in vivo and in vitro studies. Sante 14 (2004) 205-209 (in French).
5. Priotto G., Kabakyenga J., Pinoges L., et al. Artesunate and sulfadoxine-pyrimethamine combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Uganda: a randomized, double-blind, placebo-controlled trial. Trans R Soc Trop Med Hyg 97 (2003) 325-330
6. Schellenberg D., Menendez C., Kahigwa E., et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 357 (2001) 1471-1517
7. Aponte J.J., Schellenberg D., Egan A., et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet (2009) 10.1016/S0140-6736(09)61258-7 published online Sept 17.
8. Gosling R.D., Gesase S., Mosha J.F., et al. Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 10.1016/S0140-6736(09)60997-1 published online Sept 17.
9. Evans S.J., and Waller P.C. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol 43 (1997) 665
10. Slutsker L.M., Khoromana C.O., Payne D., et al. Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome. Bull World Health Organ 68 (1990) 53-59
11. Luxemburger C., Price R.N., Nosten F., Ter Kuile F.O., Chongsuphajaisiddhi T., and White N.J. Mefloquine in infants and young children. Ann Trop Paediatr 16 (1996) 2818-2906
12. White N.J. Intermittent presumptive treatment for malaria: a better understanding of the pharmacodynamics will guide more rational policymaking. PLoS Med 2 (2005) 29-33